ANALYSISApril 13, 2026
Should the government negotiate prescription drug prices?
The U.S. government is actively negotiating prescription drug prices for Medicare through the Inflation Reduction Act, signed in 2022, with three rounds of negotiations now underway or complete. Separately, the Trump administration issued a 'Most-Favored-Nation' executive order on May 12, 2025, securing agreements with nine major pharmaceutical manufacturers to align U.S. drug prices with the lowest prices paid by other developed nations. The debate has shifted from whether the government should negotiate drug prices to how it should do so.
When the government negotiates drug prices, does it save patients money or kill the next miracle drug before it's invented? The answer depends entirely on whether you think profit is the engine of medical progress or just the price we pay for it.
Not familiar with this story? Get context →
Whether the baseline market was legitimate
C
Before defending or attacking the IRA, both sides need to reckon with what we're actually arguing about. The 2003 non-interference clause didn't reflect a free market — it was lobbied into existence to prohibit Medicare from using its own purchasing leverage. The baseline we've been 'protecting' for two decades was constructed by the pharmaceutical industry, not by competition.
L
We agree on the diagnosis, which makes the conservative resistance to the cure harder to explain. If the pre-IRA system was a captive buyer created by statute — a $145 billion annual purchaser legally forbidden from negotiating — then the IRA isn't government intrusion into a functioning market. It's the government recovering a normal commercial right that lobbying stripped away.
C
Agreeing on the diagnosis doesn't mean accepting any remedy. A system distorted by one political intervention doesn't become sound by adding another — and replacing a lobbied prohibition with a coercive administered-pricing apparatus is not 'recovering a normal commercial right.'
L
The alternative you're gesturing at — reference pricing, importation, generic pathways — has been available for decades and never materialized into legislation. The IRA is the reform that actually passed and survived federal court review. At some point, the perfect becomes the enemy of the real.
IRA negotiation versus coercive price control
C
The IRA calls its mechanism 'negotiation,' but genuine negotiation requires both parties to be able to walk away. Here, manufacturers face a 1,900% daily sales tax on non-compliance and statutory barriers to exiting Medicare. That's not a contract — that's administered pricing with a coercion premium. The constitutional challenge may not prevail, but the economic distortion is real regardless of what courts decide.
L
The Third Circuit already reviewed those exact terms and ruled the program doesn't violate manufacturers' constitutional rights. But more fundamentally — Medicare represents roughly 40% of the U.S. drug market. Any negotiation with a buyer that large involves significant pressure. That's not coercion; that's what leverage looks like, and it's what every other national health system in the world already uses.
C
The Third Circuit ruling addresses constitutional rights, not economic structure. No other national health system imposes a 1,900% penalty for refusing to participate — they use monopsony leverage, yes, but within legal frameworks that acknowledge manufacturers can decline. The penalty structure here is genuinely without peer.
L
A penalty that has never been triggered because manufacturers have universally chosen to negotiate rather than exit suggests the 'coercion' framing overstates the practical reality — the mechanism works, and it works without the catastrophic standoffs the conservative framing implies.
IRA's actual impact on innovation
C
The IRA's asymmetric timelines are a structural design flaw, not a theoretical concern — nine years before small-molecule drugs face negotiation, thirteen years for biologics. That differential systematically redirects R&D investment toward expensive biologics and away from traditional pills, which means the patients harmed will be precisely the chronic-condition patients the IRA claims to protect.
L
Private R&D spending has continued to increase since the IRA passed in 2022, which is the actual empirical test of the innovation-harm prediction — and that prediction is failing it. You're projecting pipeline damage from a structural differential that has existed for three years, targeting only drugs already past market exclusivity, on drugs that have already returned their initial investment many times over.
C
Three years is not enough time to see pipeline distortions — drug development cycles run a decade or more. You're declaring the innovation argument 'speculative' based on a measurement window that literally cannot capture the harm you claim isn't happening.
L
That's a fair methodological point, which is why liberals should acknowledge the pill-penalty asymmetry as a genuine drafting flaw worth fixing — rather than treating every innovation argument as industry capture. But fixing a timeline differential doesn't require dismantling the negotiation program.
Executive MFN orders versus statutory reform
C
The Trump Most-Favored-Nation approach — forcing manufacturers to justify why an American Medicare patient pays $1,000 for Ozempic while a German patient pays a fraction — is market-correcting rather than market-replacing. It exposes the absurdity of American prices through transparency and reference pricing without building a permanent expanding HHS bureaucracy.
L
The first MFN executive order was blocked by federal courts in 2020 and never took effect. You're proposing to replace a program that has survived Third Circuit review and completed three rounds of negotiations with an enforcement mechanism that has already been stopped once in court and whose 2025 terms haven't been publicly disclosed. That's not a reform — it's a rollback dressed as an alternative.
C
The IRA's scope is expanding — 10 drugs in Round 1, 15 in Round 2, 15 more in Round 3 including Part B drugs for the first time. You're defending the durability of a statutory mechanism by pointing to how much it's grown. That's not reassurance; that's the concern.
L
An expanding program targeting more of the highest-spend drugs without generic alternatives is the mechanism working as intended — not administrative capture. The alternative, executive agreements that evaporate with administrations, is precisely how 20 years of 'reform' conversations produced zero durable price relief.
Whether savings reach actual patients
C
Even if we accept the IRA's projected savings numbers, there's a structural accountability gap: some beneficiaries are paying more for negotiated drugs in 2026 because insurers restructured Part D formularies after prices were set. When the government sets a price without mandating how it flows to patients, insurers capture the arbitrage. This isn't a minor implementation glitch — it directly undermines the equity argument for the program.
L
You're right that formulary restructuring is a real problem — but notice what that argument actually demands: tighter pass-through regulations on Part D insurers, not repeal of negotiation. The answer to imperfect execution of a sound policy is to fix the execution. What it cannot logically support is restoring the non-interference clause that guaranteed every beneficiary paid full manufacturer price with zero possibility of savings.
C
We agree on the fix — stronger pass-through requirements. The point is that this is exactly the pattern of administrative pricing: each intervention generates downstream distortions requiring another layer of administrative correction. That's not a reason to repeal the IRA, but it's a reason to be clear-eyed about the governance complexity you're accumulating.
L
Every major government program generates implementation problems that require regulatory refinement — that's not a unique indictment of drug price negotiation. The relevant comparison isn't between the IRA and a perfect system; it's between the IRA with fixable formulary problems and two decades of a statutory prohibition that guaranteed American patients paid 3.5 times the OECD price with no recourse at all.
Conservative's hardest question
The claim that the IRA damages pharmaceutical innovation is genuinely contested: R&D spending has continued to rise since 2022, and separating IRA effects from broader industry investment cycles requires a longer time horizon than currently exists. A critic can fairly say this argument is speculative about future harm while the cost savings to Medicare beneficiaries are documented and near-term.
Liberal's hardest question
The concern that some Medicare beneficiaries are actually paying more for negotiated drugs in 2026 — because insurers restructured Part D formularies after prices were set — is not a minor implementation glitch. If program-level savings do not reliably reach individual patients, the core equity argument for the IRA is undermined, and the gap between projected savings and actual beneficiary experience becomes a serious accountability failure that liberal advocates cannot afford to minimize.
Both sides agree: Both sides agree that the pre-IRA status quo — a $145 billion annual buyer legally prohibited from negotiating — was not a functioning market but a politically constructed arrangement that systematically overcharged American patients relative to every peer nation.
The real conflict: They disagree on a question of fact and classification: whether the IRA process constitutes genuine negotiation or administered price control, with the 1,900% non-compliance tax and Medicare exit barriers as the specific evidence in dispute.
What nobody has answered: If program-level savings from IRA negotiations are not reliably reaching individual Medicare beneficiaries because insurers are restructuring formularies to capture the margin, then who exactly is the policy helping — and does the answer change the moral case for negotiation itself?
Sources
- CMS Medicare Drug Price Negotiation Program announcements (Rounds 1, 2, and 3)
- Inflation Reduction Act of 2022 (P.L. 117-169)
- Trump Administration Executive Order, 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,' May 12, 2025
- U.S. Court of Appeals for the Third Circuit ruling on Janssen/BMS v. HHS, September 2025
- CMS projected savings estimates for IRA Round 1 negotiations
- RAND Corporation and CMS data on U.S. vs. OECD drug price comparisons
- Lobbying disclosure data on Medicare price negotiation legislation
- Medicare Part D enrollment and spending data (2023)